Clinical trials

1

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults

This study is designed to test whether QBKPN SSI can improve immune function in older adults, including how well it can protect against respiratory and other infections, whether it improves the body's response to COVID-19 vaccines, what effect it has on maintaining or improving quality of life, activity level and health status and whether it has an effect on glycemic control. QBKPN is a new medication in a class known as Site-Specific Immunomodulators (SSI). SSIs are designed to train and/or improve innate immune function to reduce the risk of infections, improve immune response to cancer, and slow the progression of chronic inflammatory diseases. It is believed that QBKPN SSI can work with the immune system to help protect against respiratory and other infections.

Participants needed: 72
Trial details
Phase: Phase 2Age: 65+Biological sex: AllType: InterventionalSponsor: Qu Biologics Inc.Updated: Jan 22, 2025Locations: 1
Eligibility criteria

Be a resident of the community or a long-term care, independent-living or assist... [+3]

Life expectancy of less than 3 months due to terminal illness as determined by t... [+6]